drugset / Trial / NCT05419401
A Study to Investigate the Absolute Bioavailability, Absorption, Metabolism, Distribution and Excretion of [14C]AZD5363 (Capivasertib)
NaSequentialOpen-labelTreatment
Summary
The Sponsor is developing the test medicine, Capivasertib, for the potential treatment of primary breast and prostate cancer. This two-part healthy volunteer study will try to identify the absolute bioavailability (amount of the test medicine that enters the blood stream), mass balance recovery (how much radioactivity can be recovered from the urine and faeces) and the rates and routes of elimination of the test medicine.
Timeline
- Start
- 2022-04-11
- Primary completion
- 2022-07-12
- Completion
- 2022-07-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capivasertib | Small molecule | 100 ug | Oral |
| Subject | Capivasertib | Small molecule | 200 mg | Oral |
| Subject | Capivasertib | Small molecule | 400 mg | Oral |
Indications
No indication recorded.